Riskpilot← Back to searchSign inGet full accessScanleaf ApS
APSDissolvedCVR 39900351Stubmarken 5Manufacture of pharmaceutical preparations · NACE 2120Est. 2018— employees
Revenue 2024
DKK -131K
-54% vs 2023
EBITDA margin
100.0%
+54% vs 2023
Equity ratio
-28.9%
Financial strength
Net profit 2024
DKK -219K
+46% vs 2023
| Revenue | DKK -131K | -54% |
| EBITDA | DKK -131K | +54% |
| Net profit | DKK -219K | +46% |
| Total assets | DKK 1,2M | +999% |
| Equity | DKK -353K | -163% |
| Employees | — | — |
Legal name
Scanleaf ApS
CVR number
39900351
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
29. september 2018
Share capital
DKK 40.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en direktør.
Address
Stubmarken 5
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | -72 | -30 | -93 | -62 | -283 | -131 |
| Staff expenses | -0 | -50 | -0 | -0 | -0 | -0 |
| EBITDA | -72 | -80 | -93 | -62 | -283 | -131 |
| Depreciation & amort. | -59 | -126 | -118 | -117 | -117 | -59 |
| EBIT | -130 | -206 | -211 | -179 | -401 | -189 |
| Net financials | -0 | -2 | -1 | -1 | -5 | -29 |
| Profit before tax | -131 | -208 | -212 | -180 | -405 | -219 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -131 | -208 | -212 | -180 | -405 | -219 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 883 | 676 | 463 | 307 | 111 | 1.222 |
| Equity | 871 | 664 | 451 | 271 | -134 | -353 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 12 | 12 | 12 | 35 | 245 | 1.575 |
| Total debt | 12 | 12 | 12 | 35 | 245 | 1.575 |
EBITDA margin
-13065100.0%
This company
15.8%
Market median
-82690606% vs market
20192024
Equity ratio
-28.9%
This company
38.2%
Market median
-176% vs market
20192024
Return on equity
-21858200.0%
This company
18.4%
Market median
-118794665% vs market
20192024
Net profit margin
-21858200.0%
This company
8.1%
Market median
-269854421% vs market
20192024
Asset turnover
-0.11×
This company
1.12×
Market median
-110% vs market
20192024
Debt / equity
4.46×
This company
0.62×
Market median
-619% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-09-29 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PE Management | Management | 2025 | — | — |
HH Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
rightQA.dk Consultancy ApS | Company | 5.0% | 5.0% | 2022 |
168 aps | Company | 50.0% | 50.0% | 2022 |
| Individual | 50.0% | 50.0% | 2019 | |
Herlevsen Holding ApS | Company | 20.0% | 20.0% | 2022 |
Redhare ApS | Company | 20.0% | 20.0% | 2022 |
Valcon Medical A/S | Company | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Scanleaf ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Emil Guldmann Sigetty | Management | 0 companies |
| Hasse Herlevsen | Chief Executive Officer | 0 companies |
| Pete Patterson | Chairman | 0 companies |
| Mike Steen Hansen | Board of Directors | 0 companies |